Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Centre Muraz | OTHER |
| Medical Research Council | OTHER_GOV |
| Institut Pasteur | INDUSTRY |
| REVS PLUS Burkina Faso |
Not provided
Not provided
Not provided
Not provided
The TRI-MOM program aims to implement and evaluate a simplified (based on inexpensive rapid diagnostic tests), integrated (in governmental health facilities) and coordinated (between health care workers) strategy for the triple elimination of HIV, syphilis and HBV mother-to-child transmission (MTCT) in nine maternal and child health services, 5 in Burkina Faso and 5 in The Gambia.
The TRI-MOM program has two components:
The TRI-MOM (TRIple elimination Model Of Mother-to-child transmission of HIV/Syphilis and HBV in Burkina Faso and The Gambia) program aims to implement and evaluate a simplified (based on inexpensive rapid diagnostic tests), integrated (in governmental health facilities) and coordinated (between health care workers) strategy for the triple elimination of HIV, syphilis and HBV MTCT in nine maternal and child health services, 5 in Burkina Faso and 5 in The Gambia. In The Gambia, the program will be conducted in collaboration with the national HIV, sexually transmitted infections (STI) and hepatitis programmes.
The TRI-MOM program has two components:
Intervention component :
The TRI-MOM strategy includes 4 main activities:
Evaluation component :
The TRI-MOM program will include three studies :
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| TRI-MOM | Experimental | Women attending their first postnatal visit in one of the selected maternities (no maternal age limit) will be eligible to participate in the study |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| TRI-MOM intervention | Other | The TRI-MOM strategy includes 4 main activities:
|
| Measure | Description | Time Frame |
|---|---|---|
| Coverage of the strategy in the study maternities before its implementation | Proportion of women screened for HIV, Syphilis and HBV during pregnancy | Assessed cross-sectionally using a questionnaire administered to women at baseline (before the implementation of the TRI-MOM strategy) |
| Coverage of the strategy in the study maternities after its implementation | Proportion of women screened for HIV, Syphilis and HBV during pregnancy | Assessed cross-sectionally using a questionnaire administered to women at 12 months (after the implementation of the TRI-MOM strategy) |
| Measure | Description | Time Frame |
|---|---|---|
| Knowledge of the targeted infections before the strategy implementation | Proportion of women with a good level of knowledge (defined by a score) of the targeted infections (HIV, syphilis, and HBV) and of PMTCT | Assessed cross-sectionally using a questionnaire administered to women at baseline (before the implementation of the TRI-MOM strategy) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Lauren Perieres, PhD | Contact | +33 4.91.32.46.00 | lauren.perieres@inserm.fr |
| Name | Affiliation | Role |
|---|---|---|
| Sylvie Boyer, PhD | UMR 1252 SESSTIM | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Centre Muraz/INSP | Not yet recruiting | Bobo-Dioulasso | Burkina Faso |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 41649980 | Derived | Vo-Quang E, Guingane AN, Perieres L, Ndow G, Some V, Badjie S, Jobe A, Gouem C, Shimakawa Y, Kania D, Lemoine M, Boyer S; TRI-MOM study group. Towards triple elimination of HIV, syphilis and HBV mother-to-child transmission: Protocol of a simplified and integrated strategy in Burkina Faso and The Gambia: Protocol for the phase 1 of the TRI-MOM project. PLoS One. 2026 Feb 6;21(2):e0322670. doi: 10.1371/journal.pone.0322670. eCollection 2026. |
Not provided
Not provided
To be completed
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D000163 | Acquired Immunodeficiency Syndrome |
| D013587 | Syphilis |
| D006509 | Hepatitis B |
| ID | Term |
|---|---|
| D015658 | HIV Infections |
| D000086982 | Blood-Borne Infections |
| D003141 | Communicable Diseases |
| D007239 | Infections |
Not provided
Not provided
| UNKNOWN |
| Young Gambian Mums Fund | UNKNOWN |
| National AIDS Control Program Gambia | UNKNOWN |
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Knowledge of the targeted infections after the strategy implementation | Proportion of women with a good level of knowledge (defined by a score) of the targeted infections (HIV, syphilis, and HBV) and of PMTCT | Assessed cross-sectionally using a questionnaire administered to women at 12 months (after the implementation of the TRI-MOM strategy) |
| Acceptability of the implemented strategy and PMTCT and preferences : screening refusal before the strategy implementation | Proportion of pregnant women who refuse the screening for any of the 3 targeted infections | Assessed cross-sectionally using a questionnaire administered to women at baseline (before the implementation of the TRI-MOM strategy) |
| Acceptability of the implemented strategy and PMTCT and preferences : screening refusal after the strategy implementation | Proportion of pregnant women who refuse the screening for any of the 3 targeted infections | Assessed cross-sectionally using a questionnaire administered to women at 12 months (after the implementation of the TRI-MOM strategy) |
| Acceptability of the implemented strategy and PMTCT and preferences : treatment refusal before the strategy implementation | Proportion of positive pregnant women refusing treatment | Assessed cross-sectionally using a questionnaire administered to women at baseline (before the implementation of the TRI-MOM strategy) |
| Acceptability of the implemented strategy and PMTCT and preferences : treatment refusal after the strategy implementation | Proportion of positive pregnant women refusing treatment | Assessed cross-sectionally using a questionnaire administered to women at 12 months (after the implementation of the TRI-MOM strategy) |
| Sensitivity of the hepatitis B core-related antigen rapid diagnostic test (HBcrAg-RDT) (PROTECT-B ancillary study) | Percentage of HBsAg-positive women with a high viral load (≥200,000 IU/mL) who are positive for HBcrAg-RDT | Data collected at cohort inclusion |
| Specificity of the HBcrAg-RDT (PROTECT-B ancillary study) | Percentage of HBsAg-positive women with a low viral load <200,000 IU/mL who are negative for HBcrAg-RDT | Data collected at cohort inclusion |
| Positive predictive value of the HBcrAg-RDT (PROTECT-B ancillary study) | Proportion of subjects with a positive HBcrAg test result who truly have a high viral load (≥200,000 IU/mL) | Data collected at cohort inclusion |
| Negative predictive value of the HBcrAg-RDT (PROTECT-B ancillary study) | Proportion of subjects with a negative HBcrAg test result who truly do not have a high viral load (≥200,000 IU/mL) | Data collected at cohort inclusion |
| MRC The Gambia at LSHTM | Recruiting | Fajara | The Gambia |
|
| D015229 |
| Sexually Transmitted Diseases, Viral |
| D012749 | Sexually Transmitted Diseases |
| D016180 | Lentivirus Infections |
| D012192 | Retroviridae Infections |
| D012327 | RNA Virus Infections |
| D014777 | Virus Diseases |
| D012897 | Slow Virus Diseases |
| D000091662 | Genital Diseases |
| D000091642 | Urogenital Diseases |
| D007153 | Immunologic Deficiency Syndromes |
| D007154 | Immune System Diseases |
| D014211 | Treponemal Infections |
| D013145 | Spirochaetales Infections |
| D016905 | Gram-Negative Bacterial Infections |
| D001424 | Bacterial Infections |
| D001423 | Bacterial Infections and Mycoses |
| D015231 | Sexually Transmitted Diseases, Bacterial |
| D018347 | Hepadnaviridae Infections |
| D004266 | DNA Virus Infections |
| D006525 | Hepatitis, Viral, Human |
| D006505 | Hepatitis |
| D008107 | Liver Diseases |
| D004066 | Digestive System Diseases |